Wedbush Securities’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Wedbush Securities’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-11,044	Closed	-$7K	–	816
2015 Q1	$7K	Hold	11,044	–	–	﹤0.01%	735
2014 Q4	$9K	Buy	+11,044	New	+$7.54K	﹤0.01%	707

Other funds holding GCVRZ

Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return

Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Wedbush Securities's GCVRZ Position: Q2 2015 in Review

Wedbush Securities sold out of Sanofi Contingent Value Rights (GCVRZ) in Q2 2015, closing a stake of 11,044 shares — an estimated $7K sold.

Wedbush Securities first reported a position in GCVRZ in Q4 2014 and held it in 2 quarters. The position peaked at $9K in Q4 2014. 116 funds tracked by Wall St. Rank hold GCVRZ as of Q2 2015.

Wedbush Securities reported no remaining Sanofi Contingent Value Rights position as of Q2 2015 after selling out during the quarter.
Wedbush Securities sold 11,044 Sanofi Contingent Value Rights shares in Q2 2015, an estimated $7K.
Wedbush Securities first reported a position in Sanofi Contingent Value Rights in Q4 2014 and held it in 2 quarters.
Wedbush Securities's Sanofi Contingent Value Rights position peaked at $9K in Q4 2014.
116 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q2 2015.

Based on Wedbush Securities's 13F filing for Q2 2015, filed 10 Aug 2015.